Interleukin (IL)-16, a multifunctional cytokine, plays a fundamental role in inflammatory diseases, as well as in the development and progression of tumors. Genetic variation in the DNA sequence of the IL-16 gene may lead to altered cytokine production and/or activity, and this variation may modulate an individual's susceptibility to both colorectal cancer (CRC) and gastric cancer (GC). To test this hypothesis, we investigated the association of IL-16 gene polymorphisms with serum levels of IL-16 and the risk of CRC and GC in a Chinese population. We analyzed singlenucleotide polymorphisms of the IL-16 gene in 596 cancer patients (376 patients with CRC and 220 patients with GC), and also in 480 age-and sex-matched controls using polymerase chain reactionrestriction fragment length polymorphism and DNA sequencing methods. Serum IL-16 levels were measured by enzyme-linked immunosorbent assay. The rs11556218 T/G polymorphism of the IL-16 gene was significantly associated with the susceptibility to CRC and GC patients. Both male and female patients carrying the G allele had a significantly higher risk for developing CRC and GC compared with individuals carrying the T allele. Alternatively, women carrying the T allele (rs4072111 C/T) showed a decreased risk for CRC and GC compared with individuals carrying the C allele. In patients with CRC or GC, IL-16 serum levels were significantly higher than those in the healthy controls, although no significant association between IL-16 polymorphisms and serum levels of IL-16 was observed. Our data indicate that IL-16 polymorphisms may contribute to CRC and GC susceptibility.
Introduction
Increasing evidence from preclinical and clinical studies has identified inflammation as a risk factor for cancer (1, 2) . Approximately, 25% of all cancer cases worldwide correlate with cases of chronic infection and inflammation (3) , with patients with chronic inflammatory disease exhibiting a much higher risk for tumor formation and progression. For example, patients suffering from inflammatory bowel disease, such as ulcerative colitis and Crohn's colitis, are at an increased risk of developing colorectal cancer (CRC) (4) , and subjects with Helicobacter pylori infection have an increased risk of developing gastric cancer (GC) (3) . The exact mechanisms that mediate inflammation and subsequently contribute to carcinogenesis is still unclear.
Both inflammatory cells and tumor cells produce cytokines and chemokines to facilitate tumor promotion and progression (2, 5) . Cytokines such as tumor necrosis factor-a (6,7), interleukin (IL)-1b (8) , and IL-15 (11) , as well as a range of chemokines (12) (13) (14) , have been reported to play pivotal roles in various human cancers, including CRC and GC. IL-16 is considered a proinflammatory cytokine and was originally identified as lymphocyte chemoattractant factor in 1982 (15) . The IL-16 gene is located on chromosome 15q26.3 in humans and encodes two distinct isoforms, leukocyte IL-16 (isoform 1) and neuronal IL-16 (isoform 2), which derive from two different transcription variants (16) . IL-16 is precursor protein consisting of 631 amino acids that is cleaved by caspase-3 to form the active C-terminal domain containing 121 amino acids (17) (18) (19) . IL-16 is produced by activated CD8þ T cells (20) , mast cells (21) and B cells (22) and can selectively activate CD4þ T cells, monocytes, macrophages, eosinophils and dendritic cells by binding the CD4 receptor (23, 24) . Furthermore, IL-16 can promote the secretion of tumor-associated inflammatory cytokines (i.e. tumor necrosis factor-a, IL-1b, IL-6 and IL-15) by monocytes (25) . All these cytokines have been demonstrated to play a critical role in the pathogenesis of human cancers (6) (7) (8) (9) (10) (11) . Recently, the role of IL-16 in tumorigenesis has been explored (26) (27) (28) (29) (30) (31) (32) , with upregulation of IL-16 expression demonstrated in both human and rat gliomas in vivo (27) and the identification of IL-16 as a candidate susceptibility gene in prostate cancer (30) . Higher serum levels of IL-16 have also been associated with advanced stages of cancer (26, 28) and a worse patient outcome depending on the type of tumor (29) . The possible mechanisms induced by IL-16 include the p56 lck tyrosine kinase, the stress-activated protein kinase pathway and the p38 mitogen-activated protein kinase pathway (33, 34) .
These reports highlight the important role that IL-16 may play in the pathogenesis of cancer. While the majority of studies on IL-16 gene polymorphisms have focused on inflammatory and autoimmune diseases (35) (36) (37) (38) (39) (40) (41) (42) , no studies to date have examined the association between single-nucleotide polymorphisms (SNPs) of the IL-16 gene and CRC and GC. Moreover, the effect of IL-16 gene polymorphisms on serum levels of IL-16 remains unknown. Therefore, the aim of this study was to investigate the relationship between IL-16 gene polymorphisms and the incidence of CRC and GC and the influence of SNPs on IL-16 serum levels in patients with CRC and GC versus healthy controls.
Materials and methods

Study population
This study included 596 cancer patients (376 patients with CRC and 220 patients with GC) and 480 non-cancer controls. Patients were recruited from the West China Hospital, Sichuan University and were unrelated Chinese individuals residing in China between July 2005 and March 2007 (Table I) . Diagnosis of carcinoma was confirmed by histopathological examination. Patients with CRC (226 males, 150 females) had a mean (standard deviation) age of 60.3 (13.2) years. Patients with GC (146 males, 74 females) had a mean age of 57.9 (11.9) years. Control subjects included 480 healthy volunteers who visited the general health checkup division of the West China Hospital, Sichuan University. Control group subjects were selected based on an absence of any evidence or personal or family history of cancer or inflammatory diseases, such as gastritis, ulcerative colitis and Crohn's colitis. The mean age of the control group (306 males, 174 females) was 58.8 (11.2) years. Written informed consent was obtained from all subjects participating in this study, and the study was performed with the approval of the ethics committee of the Chinese Human Genome. Serum IL-16 levels Blood samples were obtained from subjects with and without cancer, centrifuged and stored at À80°C until analysis. Serum IL-16 levels were determined by enzyme-linked immunosorbent assay (USCNLIFE, Missouri City, TX) according to the manufacturer's instructions. The minimum level of detection for IL-16 was 0.10 pg/ml. No cross-detection of other cytokines was observed. Each sample was assayed in duplicate and the intra-assay coefficient of variation was ,10%.
Genotyping
Statistical analysis
Genotype and allele frequencies of IL-16 were compared between subjects with and without cancer using the v 2 test and Fisher's exact test when appropriate. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated to assess the relative risk conferred by a particular allele and genotype. Demographic and clinical data among groups were compared using the v 2 test and the Student's t-test. Hardy-Weinberg equilibrium was tested with a goodness of fit v 2 test with one degree of freedom to compare the observed genotype frequencies among the subjects with the expected genotype frequencies. Differences in IL-16 serum levels among patients with CRC or GC versus control subjects were examined using the Mann-Whitney U test. Statistical significance was set at P , 0.05. The SPSS statistical software package version 11.5 was used for all statistical analyses.
Results
Characteristics of the study subjects Table I summarizes the characteristics of the 596 cancer patients (376 patients with CRC and 220 patients with GC) and 480 non-cancer control subjects included in this study. No significant differences in age, gender distribution or smoking and alcohol consumption status were identified between cancer patients and control subjects, suggesting that subject matching based on these variables was adequate.
Genotype and allele frequencies of IL-16
Among the six SNPs investigated in this study for IL-16, rs17875513 C/T, rs17875553 G/T and rs34460207 A/G were not present in any of the CRC, GC or control subjects. Therefore, these three sites were excluded from subsequent analysis. The genotype and allele frequencies of the three additional polymorphisms considered in this study, rs4778889 T/C, rs11556218 T/G and rs4072111 C/T, are summarized in Table III . The genotype distributions of these three polymorphisms in control subjects were present in Hardy-Weinberg equilibrium. For the rs11556218 T/G, there was significant difference in the genotype and allele frequencies of this polymorphism among CRC, GC and control subjects. The frequencies of the TT, TG and GG genotypes of rs11556218 T/G were 55.2, 41.0 and 3.8% in controls; 38.0, 58.2 and 3.7% in patients with CRC and 42.7, 50.9 and 6.4% in patients with GC, respectively. The TG genotype was associated with a significantly higher risk of CRC as compared with the TT genotype (adjusted OR 5 2.06; 95% CI, 1.56-2.74). Alternatively, the TG and GG genotypes were associated with a significantly higher risk of GC compared with patients with the TT genotype (adjusted OR 5 1.62; 95% CI, 1.17-2.26 and adjusted OR 5 2.24, 95% CI, 1.07-4.70, respectively). Using the T allele as a reference, a significant correlation was detected between the presence of the G allele and a risk of developing both CRC (adjusted OR 5 1.53; 95% CI, 1.23-1.89) and GC (OR 5 1.47; 95% CI, 1.15-1.89). However, genotype and allele frequencies of the IL-16 rs4778889 T/C and rs4072111 C/T polymorphisms in CRC and GC patients were not significantly different from those in healthy controls (P . 0.05).
Stratified analysis
When analyses of genotype and allele frequencies were stratified by gender, significant differences in the distributions of the IL-16 gene polymorphisms among patients with CRC and GC and control groups were observed (Tables IV and V) . Men, who carried the IL-16 (rs11556218 T/G) G allele, were associated with a 1.56-fold increased risk of CRC and a 1.53-fold increased risk of GC compared with patients carrying the T allele (for CRC: adjusted OR 5 1.56; 95% Similarly, women who carried the IL-16 (rs11556218 T/G) G allele also showed a 1.46-fold increased risk of CRC compared with patients carrying the T allele (adjusted OR 5 1.46; 95% CI, 1.04-2.04). However, women carrying the IL-16 (rs4072111 C/T) T allele showed a decreased risk for both CRC and GC compared with women carrying the C allele (for CRC: adjusted OR 5 0.54; 95% CI, 0.36-0.80; for GC: adjusted OR 5 0.52; 95% CI, 0.31-0.86). When patients were divided according to their tumor stage, comparisons of IL-16 genotype and allele frequencies showed no significant differences among any subgroup of CRC or GC patients (data not shown).
Serum IL-16 levels and polymorphism
The median serum concentration of IL-16 detected was 7.09 ng/ml (range 0.03-35.44 ng/ml) in CRC patients (n 5 60), 6.37 ng/ml (range 0.07-35.45 ng/ml) in GC patients (n 5 55) and 3.23 ng/ml (range Association of IL-16 with colorectal and gastric cancer 0.06-24.18 ng/ml) in healthy control subjects (n 5 61). The serum levels of IL-16 detected in cancer patients were significantly different from those in the healthy control subjects (P , 0.05). However, when studying the relationship between the IL-16 polymorphisms present and serum levels among patients with CRC, GC, and healthy controls, we found no significant differences, nor did we find any correlation between genotype and pathological indices of CRC and GC severity (data not shown).
Discussion
To our knowledge, this is the first study to investigate whether IL-16 gene polymorphisms are related to the occurrence of CRC or GC in a Chinese population and whether IL-16 gene polymorphisms correlate with serum levels of IL-16. Our results showed that the rs11556218 T/G polymorphism of the IL-16 gene, an asparagine (Asn) to lysine (Lys) substitution in exon 6 of the IL-16 gene, was significantly associated with patient susceptibility to CRC and GC, with both male and female patients carrying the G allele (rs11556218 T/G) having a significantly higher risk for developing CRC and GC. In contrast, the non-synonymous SNP, rs4072111 C/T, representing a serine (Ser) to proline (Pro) substitution, was predictive of CRC or GC risk in female patients. For example, women carrying the T allele of the rs4072111 C/T polymorphism had a decreased risk for CRC and GC compared with female patients carrying the C allele. Despite the correlations between the rs11556218 T/G and rs4072111 C/T polymorphisms and the incidence of CRC and GC observed in this study, the serum levels of IL-16 detected in these groups of patients did not show any significant differences other than a cumulatively higher level of serum IL-16 in patients with CRC or GC relative to the healthy controls. Our findings are consistent with previous studies that reported higher serum levels of IL-16 in cancer patients, including patients with gastrointestinal cancer (26, 28) . In combination, these data indicate that there is no association between IL-16 polymorphisms and IL-16 serum levels. However, the results of our study suggest that IL-16 gene polymorphisms may be useful as genetic susceptibility markers for both CRC and GC. In this study, we selected the common SNP for IL-16, rs4778889 T/C [located 295 bp upstream from the start site of transcription and associated with altered levels of gene expression (43)], as well as five other SNPs to evaluate in patients with CRC, GC and healthy controls. The selection criteria for the five additional SNPs were that they are located in the region of an exon, and their single-nucleotide changes would result in an amino acid substitution. This is the first study to explore the polymorphisms of rs17875513 C/T, rs17875553 G/T and rs34460207 A/G that do not have reference data available from the National Institutes of Health SNP database (http://www.ncbi.nlm. nih.gov/projects/SNP/). None of these polymorphisms was found in the Chinese population included in this study. Previously, epidemiological studies of different ethnic groups have concentrated on the rs4778889 T/C polymorphism (35) (36) (37) (38) (39) (40) (41) (42) . Therefore, we compared the distribution of the rs4778889 T/C polymorphism of the IL-16 gene in healthy control populations between Asian and Caucasian ethnicities. Interestingly, we found that the frequency of the allele among Caucasians was not similar. Reich et al. (36) reported a significantly higher detection rate of the T allele (85.6%) and a lower detection rate of the C allele (14.4%) in their Caucasian population evaluated compared with other Caucasian populations studied (i.e. 77.9-78.4% for T and 18.4-21.6% for C) (37, 39, 41) . Since discrepancies could be attributed to the relatively small sample sizes studied, further confirmation would be provided by additional patient data. When the distribution of the rs4778889 T/C polymorphism of the IL-16 gene of previously published Caucasian controls was compared with data from the present study, only the study by Reich et al. (36) was found to be inconsistent with our data set. Cumulatively, these data suggest that the distribution of IL-16 gene frequencies might vary among the different ethnic groups, and therefore additional studies of IL-16 polymorphisms in other ethnic populations would be valuable.
Although the role of IL-16 as an important mediator in inflammatory diseases has been identified (44), very limited data are available regarding the association between IL-16 and tumor growth and progression. Passam et al. (31) reported that non-Hodgkin lymphomas patients who responded to standard treatment had lower levels of IL-16 compared with pretreatment levels. In human astrocytic brain tumors and rat C6 gliomas, Liebrich et al. (27) reported higher levels of IL-16 present. Similarly, Blaschke et al. (32) reported that IL-16 messenger RNA expression increased with the stage of cutaneous T cell lymphoma diagnosed. A few studies (26, 28, 29) have shown that serum levels of IL-16 can be associated with tumor stage in different tumor types. In multiple myeloma patients, higher levels of serum IL-16 and a lower CD4/CD8 ratio were detected which correlated with a shorter patient survival time (28) . The decrease in patient CD4/CD8 ratios was significantly associated with increased expression of human leukocyte antigen-DR by CD8þ T cells, suggesting that the decrease in CD4þ T cells in multiple myeloma may be mediated by activation of CD8þ T cells by cytokine IL-16. Without detailed information on the survival of CRC and GC for our study population, our further analysis of the role of IL-16 in cancer prognosis was prevented. However, our study provides evidence that IL-16 polymorphisms are probably to play a major role in patient susceptibility to CRC and GC. Although the molecular mechanisms by which IL-16 gene polymorphisms are associated with CRC and GC remain unclear, additional functional studies would provide valuable characterization of the molecular mechanisms by which IL-16 is involved in susceptibility to CRC and GC. Continued study of the role of IL-16 polymorphisms in patient susceptibility to CRC and GC from other ethnic populations would also be of great value.
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